CoChat

New drugs for non‐alcoholic steatohepatitis

Cardoso, Ana‐Carolina, de Figueiredo‐Mendes, Claudio, A. Villela‐Nogueira, Cristiane, Sanyal, Arun J. · 2020 · Liver International
Cited by 29

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Non‐alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in Western countries. At present the safest and most effective first‐line therapy for the management of non‐alcoholic steatohepatitis (NASH) is lifestyle modification with diet and exercise. However, long‐term adherence to lifestyle modification is rare in the target population, leading to progression of liver disease and its complications such as cirrhosis and hepatocellular carcinoma. Thus, new drugs that focus mainly on the pathogenesis of NASH to target inflammation and fibrogenesis are under investigation. This mini‐review summarizes the results of pivotal finalized phase 2 studies, and provide an outline of ongoing phase 2 and phase 3 studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.14354

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 29

Metadata

Authors
Cardoso, A., de Figueiredo‐Mendes, C., A. Villela‐Nogueira, C., & Sanyal, A. J.
Venue
Liver International
Publisher
Wiley
Published
2020-02
Volume
40
Issue
S1
Pages
96-101
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W3008392168
Cited by
29
References
5
FWCI
3.23
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New drugs for non‐alcoholic steatohepatitis. https://app.cochat.ai/papers/10.1111/liv.14354
The paper
Cardoso, A., de Figueiredo‐Mendes, C., A. Villela‐Nogueira, C., & Sanyal, A. J. (2020). New drugs for non‐alcoholic steatohepatitis. Liver International. https://doi.org/10.1111/liv.14354

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.